Redeye notes a higher OPEX than expected in the company’s Q1 report. However, this rhymes with its plans for geographical expansion, which received significant validation after the end of the quarter (the Thermo Fischer deal). We emphasise that the share is trading at a discount to its fair value and that the market fails to recognise Devyser’s high quality, robust growth trajectory, solid cash position and nearing positive cash flow.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/